KIZUNA trial KZ-2 begins in Reno and Kobe
ZNSI's second clinical trial of KIZUNA, a minimally invasive neural lace and relay linking a person's cortex to MUGEN, has begun at the KIZUNA clinical centre in Reno and at Tower Zero in Kobe.
KZ-2 follows KZ-1, a 2025 safety study of 18 participants, all of whom completed the study and 17 of whom asked to continue. KZ-2 will enrol 212 adult volunteers for 52 weeks.
Participants may withdraw at any time under Article 5 of the Harmony Charter, subject to the safe disconnection protocol. The trial is overseen by an independent board appointed by the Office of Harmony.
More on the KIZUNA page.
About ZNSI. Zaibatsu Neural Super Intelligence K.K. builds neuromorphic KIRIN wafers and MUGEN, the frontier model that never stops learning. Headquartered at Tower Zero, Shin-Kōbe. Press: [email protected]